Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TBC1 domain family, member 25 pseudogene (ENSG00000230607) is classified as a pseudogene rather than a functional protein-coding gene. It is related to the TBC1 domain family, whose active members (such as TBC1D25) are involved in important cellular processes like autophagosome maturation and Rab GTPase activation[1]. However, as a pseudogene, ENSG00000230607 does not encode a functional protein, is not considered a therapeutic target, and has no known biological function, disease association, or drug interaction. Its annotation as a pseudogene means it likely arose from gene duplication or retrotransposition and subsequently accumulated mutations rendering it non-functional[3]. Pseudogenes are segments of DNA resembling functional genes but typically contain disruptive mutations such as frameshifts or stop codons that prevent their expression as functional proteins. ENSG00000230607 does not code for a protein and is not cited in drug target or disease association literature, nor is it referenced in mechanistic or biomarker studies[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 25 pseudogene (TBC1D25P).